Taro Pharmaceutical Industries (NYSE:TARO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research report issued on Thursday. The firm set a “strong-buy” rating on the stock.

Separately, HC Wainwright downgraded Taro Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $43.00 target price on the stock. in a research note on Thursday, January 18th.

Taro Pharmaceutical Industries Trading Down 0.4 %

Shares of NYSE:TARO opened at $42.04 on Thursday. The stock has a market cap of $1.58 billion, a PE ratio of 34.46 and a beta of 0.61. The stock’s fifty day simple moving average is $42.19 and its two-hundred day simple moving average is $39.61. Taro Pharmaceutical Industries has a 1-year low of $23.92 and a 1-year high of $45.76.

Taro Pharmaceutical Industries (NYSE:TARO) last released its quarterly earnings results on Thursday, January 25th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.26. Taro Pharmaceutical Industries had a net margin of 7.48% and a return on equity of 3.26%. The company had revenue of $157.15 million for the quarter, compared to analyst estimates of $154.90 million. On average, sell-side analysts forecast that Taro Pharmaceutical Industries will post 1.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. bought a new position in shares of Taro Pharmaceutical Industries during the 2nd quarter valued at $26,000. UBS Group AG increased its holdings in shares of Taro Pharmaceutical Industries by 71.6% in the second quarter. UBS Group AG now owns 925 shares of the company’s stock worth $34,000 after buying an additional 386 shares during the period. Bank of America Corp DE increased its holdings in shares of Taro Pharmaceutical Industries by 126.5% in the first quarter. Bank of America Corp DE now owns 1,506 shares of the company’s stock worth $37,000 after buying an additional 841 shares during the period. Royal Bank of Canada lifted its stake in shares of Taro Pharmaceutical Industries by 664.0% in the 2nd quarter. Royal Bank of Canada now owns 1,039 shares of the company’s stock valued at $39,000 after acquiring an additional 903 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Taro Pharmaceutical Industries by 5,988.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,035 shares of the company’s stock valued at $39,000 after acquiring an additional 1,018 shares during the period. 91.40% of the stock is owned by hedge funds and other institutional investors.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.